Joe Duarte

Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert.  He has been a professional investor and independent analyst since 1990.  He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.  

Analyst Articles

Calm waters can be hiding places for big sharks.  This market seems to be in a steady up trend and many investors are looking to relax.  But in our opinion the calm demeanor of the S & P 500 is misleading and complacent investors could be in for a nasty surprise.   And as traders hit the beaches, and the Federal Reserve makes interest rate decisions in the next few days and weeks, the markets are increasingly vulnerable. Read More

It’s summertime, and on Wall Street that usually means low volume days and sluggish price movements.  But Rollins (NYSE: ROL), a pest-control company, has a nifty ten-year record of summer gains.  The stock has rallied 80% of the time during the summer months since 2006.  A move above $29 could… Read More

Amgen (AMGN) is well-positioned for the aging population with its osteoporosis drug Prolia ($1.5 billion in annual sales) and has the potential to increase its market share in the treatment of the condition with Romosozumab, a related drug aimed at spinal vertebral fractures in patients with osteoporosis. Romosozumab is currently… Read More

Shares of Novo Nordisk (NVO) rallied on May 25th after the U.S. Food and Drug Administration (FDA) approved the combination drug IdegLira for the treatment of type II Diabetes.  The drug combines two of Novo’s previously existing drugs; Tresiba, (insulin degludec) along with its GLP-1 agonist, Victoza (liraglutide) showed in clinical… Read More

Shares of Breakthrough Tech Portfolio component The WhiteWave Foods Company (WWAV) rallied in early market action on May 10th on the back of record setting earnings.  Revenues of $1.04 billion beat estimates of $1.02 billion while earnings of 24 cents were just below estimates. Adjusted earnings of 28 cents per share beat… Read More

Shares of BTP “Breakthrough Tech” portfolio holding Novo Nordisk (NVO) rallied on 4/28/16. The company announced “top line” results from its global Phase 3a trial of semaglutide, noting that the medication “significantly” reduces the risk of major cardiovascular events.Semaglutide is used in the treatment of type II diabetes improving control… Read More

Shares of Meridian Biosciences (VIVO) were moving steadily higher in early trading on 4/28 after the company announced its Q2 2016 earnings of 24 cents per share and revenues of $51.3 million.   Estimates were for 24 cents per share in earnings and $52.09 million in revenues for the quarter.   The… Read More

 Rollins (NYSE: ROL) beat revenue estimates in its quarterly earnings (for the period ending March)  report released this morning, though profits were in line at 15 cents per share. Despite the good news, and its recent important acquisitions, shares held steady in early trading. This is a great opportunity to buy… Read More